What have animal models taught us about the p53 pathway?

Mouse models have provided important insight into the in vivo significance of upstream and downstream signals that regulate the p53 tumour suppressor. One important lesson learned from these models is that negative regulators of p53 are critical in vivo modulators of p53 activity. Additionally, upstream regulators of p53 activity, such as p19Arf and Atm, are themselves critical tumour modifiers/suppressors. The presence of multiple positive regulators of p53 and numerous downstream targets indicates a redundancy that ensures activation of the p53 pathway. Importantly, p53 plays a prominent role as a tumour suppressor in vivo by virtue of its ability both to block cell cycle progression and to induce cell death. Finally, different p53 mutants have different properties in vivo. Three missense mutations have been generated at the p53 locus and all three exhibit unique differences in their ability to contribute to the tumour phenotype. Clearly, determining the levels of p53 inhibitors, and the typing of p53 mutations in human tumours should be performed to determine the best avenue for treatment. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  G. Zambetti,et al.  p53 Tumor‐Suppressor Genes , 2005 .

[2]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[3]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[4]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[5]  T. Jacks,et al.  Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389 , 2004, Molecular and Cellular Biology.

[6]  T. Jacks,et al.  Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice , 2004, Oncogene.

[7]  T. Jacks,et al.  Defective apoptosis and B‐cell lymphomas in mice with p53 point mutation at Ser 23 , 2004, The EMBO journal.

[8]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[9]  F. Alt,et al.  p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. , 2004, Cancer cell.

[10]  U. Moll,et al.  p63 and p73: roles in development and tumor formation. , 2004, Molecular cancer research : MCR.

[11]  S. Lowe,et al.  Suppression of tumorigenesis by the p53 target PUMA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[13]  D. Green,et al.  p73 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation* , 2004, Journal of Biological Chemistry.

[14]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[15]  H. K. Sluss,et al.  Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice , 2004, Molecular and Cellular Biology.

[16]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[17]  D. Green,et al.  Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation , 2004, The Journal of cell biology.

[18]  A. Multani,et al.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.

[19]  C. Branda,et al.  Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. , 2004, Developmental cell.

[20]  S. Korsmeyer,et al.  Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. , 2003, Cancer research.

[21]  Guillermina Lozano,et al.  MDM2, an introduction. , 2003, Molecular cancer research : MCR.

[22]  Rebecca A. Ihrie,et al.  Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types , 2003, Current Biology.

[23]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[24]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[25]  S. Akira,et al.  Integral role of Noxa in p53-mediated apoptotic response. , 2003, Genes & development.

[26]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[27]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[28]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[29]  T. Greiner,et al.  Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.

[30]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[31]  G. Lozano,et al.  Disrupting TP53 in mouse models of human cancers , 2003, Human mutation.

[32]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  O. Issinger,et al.  Disruption of the Regulatory β Subunit of Protein Kinase CK2 in Mice Leads to a Cell-Autonomous Defect and Early Embryonic Lethality , 2003, Molecular and Cellular Biology.

[34]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[35]  M. E. Perry,et al.  mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation , 2003, Molecular and Cellular Biology.

[36]  M. Herlyn,et al.  p16INK4A and familial melanoma. , 2003, Methods in molecular biology.

[37]  M. Moynahan,et al.  The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans , 2002, Oncogene.

[38]  S. Cory,et al.  Apoptosomes: engines for caspase activation. , 2002, Current opinion in cell biology.

[39]  Keisuke Kuida,et al.  Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome , 2002, Nature.

[40]  E. Appella,et al.  Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.

[41]  P. Jeggo,et al.  Chk2 Is a Tumor Suppressor That Regulates Apoptosis in both an Ataxia Telangiectasia Mutated (ATM)-Dependent and an ATM-Independent Manner , 2002, Molecular and Cellular Biology.

[42]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[43]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[44]  W. El-Deiry,et al.  BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets , 2002, Molecular and Cellular Biology.

[45]  R. Ramirez-Solis,et al.  mdmx is a negative regulator of p53 activity in vivo. , 2002, Cancer research.

[46]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[47]  K. Tsai,et al.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.

[48]  T. Jacks,et al.  Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Stephen N. Jones,et al.  Generation of an Mdm2 conditional allele in mice , 2002, Genesis.

[50]  K. Kwan Conditional alleles in mice: Practical considerations for tissue‐specific knockouts , 2002, Genesis.

[51]  G. Lozano,et al.  Conditional allele of mdm2 which encodes a p53 inhibitor , 2002, Genesis.

[52]  The Polish Breast Cancer Consortium Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[53]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[54]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[55]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[56]  Jiawei Han,et al.  Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[58]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[59]  M. Serrano,et al.  Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. , 2001, Cancer research.

[60]  Curtis C. Harris,et al.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.

[61]  K. Helin,et al.  Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.

[62]  P. Chappuis,et al.  TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. , 2001, Cancer research.

[63]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[64]  Yolande F M Ramos,et al.  Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. , 2001, Cancer research.

[65]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[66]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[67]  M. Kapoor,et al.  A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. , 2001, Molecular cell.

[68]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[69]  A. Wyllie,et al.  More than one way to go. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[71]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[72]  A. Yang,et al.  p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.

[73]  M. Kastan,et al.  The many substrates and functions of ATM , 2000, Nature Reviews Molecular Cell Biology.

[74]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[75]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[76]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Lowe,et al.  PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.

[78]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[79]  Andras Nagy,et al.  Cre recombinase: The universal reagent for genome tailoring , 2000, Genesis.

[80]  S. Korsmeyer,et al.  Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[81]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[82]  M. Wolter,et al.  Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.

[83]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[84]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[85]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[86]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[87]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[88]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[89]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[90]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[91]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[92]  T. Jacks,et al.  The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.

[93]  L. Donehower,et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  T. Ouchi,et al.  The BRCA2 gene product functionally interacts with p53 and RAD51. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[95]  T. Mak,et al.  Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.

[96]  K. Sakaguchi,et al.  DNA damage activates p53 through a phosphorylation-acetylation cascade. , 1998, Genes & development.

[97]  José Luis de la Pompa,et al.  Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.

[98]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[99]  S. Lowe,et al.  E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.

[100]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[101]  A. Levine,et al.  Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J. Morgan,et al.  Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. , 1998, Science.

[103]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[104]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[105]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[106]  M. Kapoor,et al.  Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation , 1998 .

[107]  T. Ouchi,et al.  BRCA1 regulates p53-dependent gene expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[108]  G. Lozano,et al.  Mouse models dissect the role of p53 in cancer and development. , 1998, Seminars in cancer biology.

[109]  M. Kapoor,et al.  Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  C. Deng,et al.  Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways , 1998, Nature Genetics.

[111]  Y Taya,et al.  DNA damage induces phosphorylation of the amino terminus of p53. , 1997, Genes & development.

[112]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[113]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[114]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[115]  T. Ludwig,et al.  Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. , 1997, Genes & development.

[116]  P. Leder,et al.  Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. , 1997, Cancer research.

[117]  G. Zambetti,et al.  Mdm‐2: “big brother” of p53 , 1997, Journal of cellular biochemistry.

[118]  Y. Shiloh,et al.  The genetic defect in ataxia-telangiectasia. , 1997, Annual review of immunology.

[119]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[120]  D. Baltimore,et al.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. , 1996, Genes & development.

[121]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[122]  L. Donehower The p53-deficient mouse: a model for basic and applied cancer studies. , 1996, Seminars in cancer biology.

[123]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[124]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[125]  M. Oren,et al.  Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.

[126]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[127]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[128]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[129]  S. Korsmeyer,et al.  Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.

[130]  D. Grignon,et al.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. , 1995, Oncogene.

[131]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[132]  M. Lovett,et al.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.

[133]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[134]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[135]  B. Vogelstein,et al.  Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.

[136]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[137]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[138]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[139]  B. Vogelstein,et al.  No room at the p53 inn , 1993, Nature.

[140]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[141]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[142]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[143]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[144]  S. Benchimol,et al.  The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. , 1993, The EMBO journal.

[145]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[146]  B. Vogelstein,et al.  Tumour suppressor genes. No room at the p53 inn. , 1993, Nature.

[147]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[148]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[149]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[150]  B. Vogelstein,et al.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[151]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[152]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[153]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.